Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery

Advanced Drug Delivery Reviews

Volumn 65, Issue 6, 2013, Pages 822-832

  Yun, Yeonhee ^a,b   Cho, Yong Woo ^b   Park, Kinam ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b Hanyang University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

GI tract; Nanoparticles; Oral protein delivery; Peptidic ligands; Protein absorption

Indexed keywords

GASTROINTESTINAL TRACT; GI TRACT; HIGH MOLECULAR WEIGHT; MEMBRANE PERMEABILITY; ORAL PROTEIN DELIVERY; PEPTIDIC LIGANDS; PROTEIN ABSORPTION; TARGETED NANOPARTICLE;

BIOCHEMISTRY; FUNCTIONAL GROUPS; LIGANDS; NANOPARTICLES; NANOTECHNOLOGY;

PROTEINS;

AI 401; ALANYLCYSTYLASPARTYLARGINYLGLYSYLASPARTYLCYSTYLPHENYLALANYLCYSTYLGLYCINE; ALBUMIN; ARGINYLGLYCYLASPARTIC ACID; CHOLESTEROL; CLEC; CYSTYLLYSYLSERYLTHREONYLHISTIDYLPROLYLLEUCYLSERYLCYSTEINE; CYSTYLSERYLLYSYLSERYLSERYLASPARTYLTYROSYLGLUTAMYLCYSTEINE; CYSTYLTHREONYLGLYCYLSERYLCYSTEINE; ELASTIN; ELIGEN; FOLIC ACID; HEXYL INSULIN MONOCONJUGATE 2; INSULIN; LECTIN; LEUCYLARGINYLVALYLGLYCINE; LIGAND; MACRULIN; NANOCAPSULE; NANOPARTICLE; ORADEL; ORASOME; PEPTIDE; POLYMER; PROLYLALANYLVALYLLEUCYLGLYCINE; PROTEIN; QUANTUM DOT; RECOMBINANT HUMAN INSULIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ABSORPTION; ACTIVE TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GASTROINTESTINAL TRACT; GLYCOCALYX; KINETICS; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; STOMACH MUCOSA; SURFACE PROPERTY; TRANSCYTOSIS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG CARRIERS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LIGANDS; NANOPARTICLES; PEPTIDES; PROTEINS;

EID: 84878855642     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.10.007     Document Type: Review

References (134)

1. Salama N.N., Eddington N.D., Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 2006, 58:15-28.
2. Hoffman A., Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin. Pharmacokinet. 1997, 33:285-301.
3. Adessi C., Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9:963-978.
4. Adessi C., Soto C. Strategies to improve stability and bioavailability of peptide drugs. Front. Med. Chem. 2004, 1:513-527.
5. Park K., Kwon I.C., Park K. Oral protein delivery: current status and future prospect. React. Funct. Polym. 2011, 71:280-287.
6. Hussain N., Jaitley V., Florence A.T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 2001, 50:107-142.
7. Donovan M.D., Flynn G.L., Amidon G.L. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 1990, 7:863-868.
8. Ikesue K., Kopečkovà P., Kopeček J. Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. 1993, 95:171-179.
9. Saffran M., Kumar G., Savariar C., Burnham J., Williams F., Neckers D. A new approach to the oral administration of insulin and other peptide drugs. Science 1986, 233:1081-1084.
10. Fix J.A. Oral controlled release technology for peptides: status and future prospects. Pharm. Res. 1996, 13:1760-1764.
11. Lee H.J. Protein drug oral delivery: the recent progress. Arch. Pharm. Res. 2002, 25:572-584.
12. Vincent H.L., Satish D.K., George M.G., Werner R. Oral route of protein and peptide drug delivery. Peptide and protein drug delivery 1991, 691-738. Marcel Dekker, New York. H.L. Vincent (Ed.).
13. Kreuter J. Nanoparticulate systems in drug delivery and targeting. J. Drug Target. 1995, 3:171-173.
14. Madara J.L. Regulation of the movement of solutes across tight junctions. Annu. Rev. Physiol. 1998, 60:143-159.
15. Tomita M., Shiga M., Hayashi M., Awazu S. Enhancement of colonic drug absorption by the paracellular permeation route. Pharm. Res. 1988, 5:341-346.
16. Rubas W., Cromwell M.E., Shahrokh Z., Villagran J., Nguyen T.N., Wellton M., Nguyen T.H., Mrsny R.J. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci. 1996, 85:165-169.
17. Pappenheimer J.R. Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters. J. Membr. Biol. 1987, 100:137-148.
18. Barry P.H. Ionic permeation mechanisms in epithelia: biionic potentials, dilution potentials, conductances, and streaming potentials. Methods Enzymol. 1989, 171:678-715.
19. Powell D.W. Barrier function of epithelia. Am. J. Physiol. 1981, 241:G275-G288.
20. Tang V.W., Goodenough D.A. Paracellular ion channel at the tight junction. Biophys. J. 2003, 84:1660-1673.
21. Shakweh M., Ponchel G., Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv. 2004, 1:141-163.
22. Florence A.T. Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target. 2004, 12:65-70.
23. Burton P.S., Conradi R.A., Hilgers A.R. (B) Mechanisms of peptide and protein absorption: (2) transcellular mechanism of peptide and protein absorption: passive aspects. Adv. Drug Deliv. Rev. 1991, 7:365-385.
24. Giannasca P.J., Giannasca K.T., Leichtner A.M., Neutra M.R. Human intestinal M cells display the sialyl Lewis A antigen. Infect. Immun. 1999, 67:946-953.
25. Gebert A., Rothkötter H.-J., Pabst R. M cells in Peyer's patches of the intestine. Int. Rev. Cytol 1996, 91-159. Academic Press. W.J. Kwang (Ed.).
26. Frey A., Neutra M.R. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Inst. Mitt. 1997, 98:376-389.
27. Clark M.A., Hirst B.H., Jepson M.A. Lectin-mediated mucosal delivery of drugs and microparticles. Adv. Drug Deliv. Rev. 2000, 43:207-223.
28. Buda A., Sands C., Jepson M.A. Use of fluorescence imaging to investigate the structure and function of intestinal M cells. Adv. Drug Deliv. Rev. 2005, 57:123-134.
29. Jani P.U., Florence A.T., McCarthy D.E. Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int. J. Pharm. 1992, 84:245-252.
30. Kataoka K., Tabata J., Yamamoto M., Toyota T. The association of gap junctions with large particles in the crypt epithelium of the rat small intestine. Arch. Histol. Cytol. 1989, 52:81-86.
31. Lavelle E.C., Sharif S., Thomas N.W., Holland J., Davis S.S. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv. Drug Deliv. Rev. 1995, 18:5-22.
32. O'Hagan D.T. Intestinal translocation of particulates - implications for drug and antigen delivery. Adv. Drug Deliv. Rev. 1990, 5:265-285.
33. Hebden J.M., Wilson C.G., Spiller R.C., Gilchrist P.J., Blackshaw E., Frier M.E., Perkins A.C. Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm. Res. 1999, 16:1087-1092.
34. Russell-Jones G.J. Carrier-mediated transport, oral drug delivery. Encyclopedia of controlled drug delivery 1999, 1:173-184. John Wiley & Sons, New York, NY. E. Mathiowitz (Ed.).
35. Barthe L., Woodley J., Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam. Clin. Pharmacol. 1999, 13:154-168.
36. Bai J.P.F., Amidon G.L. Structural Specificity of Mucosal-Cell Transport and Metabolism of Peptide Drugs: Implication for Oral Peptide Drug Delivery. Pharm. Res. 1992, 9:969-978.
37. Shah D., Shen W.C. Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J. Pharm. Sci. 1996, 85:1306-1311.
38. Russell-Jones G.J. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv. Drug Deliv. Rev. 1996, 20:83-97.
39. Swaan P.W. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm. Res. 1998, 15:826-834.
40. Charman W.N., Porter C.J.H. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Deliv. Rev. 1996, 19:149-169.
41. Wang W. Oral protein drug delivery. J. Drug Target. 1996, 4:195-232.
42. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11:61-95.
43. Patel G., Misra A. 10 - Oral delivery of proteins and peptides: concepts and applications. Challenges in Delivery of Therapeutic Genomics and Proteomics 2011, 481-529. Elsevier, London. M. Ambikanandan (Ed.).
44. Langguth P., Bohner V., Heizmann J., Merkle H.P., Wolffram S., Amidon G.L., Yamashita S. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release 1997, 46:39-57.
45. Mrsny R. Challenges for the oral delivery of proteins and peptides: theoretical and practical approaches to their delivery 1991, 452. Capsugel Symposia Series, Greenwood, SC.
46. Ganong W.F. Regulation of gastrointestinal function. Review of medical physiology 1983, 394-420. Lange Medical Publications. 12th ed. W.F. Ganong (Ed.).
47. Mrsny R.J. Challenges for the oral delivery of proteins and peptides: theoretical and practical approaches to their delivery 1991, 45-52. Capsugel Library Symposia series.
48. Hayakawa E., Lee V.H. Aminopeptidase activity in the jejunal and ileal Peyer's patches of the albino rabbit. Pharm. Res. 1992, 9:535-540.
49. Skillman J.J., Gould S.A., Chung R.S., Silen W. The gastric mucosal barrier: clinical and experimental studies in critically ill and normal man, and in the rabbit. Ann. Surg. 1970, 172:564-584.
50. Meyer R.A., McGinley D., Posalaky Z. The gastric mucosal barrier: structure of intercellular junctions in the dog. J. Ultrastruct. Res. 1984, 86:192-201.
51. MacAdam A. The effect of gastro-intestinal mucus on drug absorption. Adv. Drug Deliv. Rev. 1993, 11:201-220.
52. Phelps C.F. Biosynthesis of mucus glycoprotein. Br. Med. Bull. 1978, 34:43-48.
53. Allen A., Garner A. Mucus and bicarbonate secretion in the stomach and their possible role in mucosal protection. Gut 1980, 21:249-262.
54. Kompella U.B., Lee V.H. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv. Drug Deliv. Rev. 2001, 46:211-245.
55. Kerss S., Allen A., Garner A. A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents. Clin. Sci. 1982, 63:187-195.
56. Crater J.S., Carrier R.L. Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol. Biosci. 2010, 10:1473-1483.
57. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
58. Lee V.H.L., Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. 1989, 4:171-207.
59. Tang B.C., Dawson M., Lai S.K., Wang Y.Y., Suk J.S., Yang M., Zeitlin P., Boyle M.P., Fu J., Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19268-19273.
60. Lai S.K., Wang Y.-Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. U. S. A. 2010, 7:59603.
61. Primard C., Rochereau N., Luciani E., Genin C., Delair T., Paul S., Verrier B. Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials 2010, 31:6060-6068.
62. Aoki Y., Morishita M., Asai K., Akikusa B., Hosoda S., Takayama K. Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm. Res. 2005, 22:1854-1862.
63. Morishita M., Morishita I., Takayama K., Machida Y., Nagai T. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 1993, 16:68-72.
64. Serra L., Josep D., Nicholas P. Engineering Design and Molecular Dynamics of Mucoadhesive Drug Delivery Systems as Targeting Agents. Eur. J. Pharm. Biopharm. 2009, 71:519-528.
65. Maria Burke S.W. Biopharmaceuticals: A New Era of Discovery in the Biotechnology Revolution 2001, PJB Publications.
66. Almeida A.J., Alpar H.O., Brown M.R. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea-pigs. J. Pharm. Pharmacol. 1993, 45:198-203.
67. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994, 81:661-667.
68. Carino G.P., Jacob J.S., Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. Release 2000, 65:261-269.
69. Emerich D.F., Thanos C.G. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 2006, 23:171-184.
70. Jahanshahi M., Zhang Z., Lyddiatt A. Subtractive chromatography for purification and recovery of nano-bioproducts. IEE Proc. Nanobiotechnol. 2005, 152:121-126.
71. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
72. Mohanraj V., Chen Y. Nanoparticles - a review. Trop. J. Pharm. Res. 2006, 5:561-573.
73. Galindo-Rodriguez S.A., Allemann E., Fessi H., Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 2005, 22:419-464.
74. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
75. McClean S., Prosser E., Meehan E., O'Malley D., Clarke N., Ramtoola Z., Brayden D. Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 1998, 6:153-163.
76. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J.X., Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur. J. Pharm. Biopharm. 2000, 50:147-160.
77. Allemann E., Gurny R., Doelker E. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 1993, 39:173-191.
78. Quintanar-Guerrero D., Allemann E., Fessi H., Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev. Ind. Pharm. 1998, 24:1113-1128.
79. Landry D.V.B.F.B., Spenlehauer G., Veillard M., Kreuter J. Influence of the coating agents on the degradation of poly(D,Llactic acid) nanoparticles in model digestive fluids. S.T.P. pharma: sciences techniques et pratiques pharmaceutiques 1996, 6:195-202.
80. Le Ray A.M., Vert M., Gautier J.C., Benoît J.P. Fate of [14C]poly(DL-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int. J. Pharm. 1994, 106:201-211.
81. Sayani A.P., Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13:85-184.
82. Ezpeleta I., Arangoa M.A., Irache J.M., Stainmesse S., Chabenat C., Popineau Y., Orecchioni A.-M. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int. J. Pharm. 1999, 191:25-32.
83. Oldenborg P.A., Gresham H.D., Chen Y., Izui S., Lindberg F.P. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 2002, 99:3500-3504.
84. Hussain N. Ligand-mediated tissue specific drug delivery. Adv. Drug Deliv. Rev. 2000, 43:95-100.
85. Lee G.Y., Kim J.-H., Oh G.T., Lee B.-H., Kwon I.C., Kim I.-S. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J. Control. Release 2011, 155:211-217.
86. Jin Y., Song Y., Zhu X., Zhou D., Chen C., Zhang Z., Huang Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 2012, 33:1573-1582.
87. V integrin ligands improves its antineoplastic activity. Cancer Res. 2004, 64:565-571.
88. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
89. Wagner E., Curiel D., Cotten M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 1994, 14:113-135.
90. Daniels T.R., Delgado T., Rodriguez J.A., Helguera G., Penichet M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121:144-158.
91. Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121:159-176.
92. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54:561-587.
93. Berry C.C., Charles S., Wells S., Dalby M.J., Curtis A.S.G. The influence of transferrin stabilised magnetic nanoparticles on human dermal fibroblasts in culture. Int. J. Pharm. 2004, 269:211-225.
94. Gupta A.K., Berry C.C., Gupta M., Curtis A.S.G. Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans. Nanobioscience 2003, 2:255-261.
95. Debelle L., Tamburro A.M. Elastin: molecular description and function. Int. J. Biochem. Cell Biol. 1999, 31:261-272.
96. Baker M.E. Albumin's role in steroid hormone action and the origins of vertebrates: is albumin an essential protein?. FEBS Lett. 1998, 439:9-12.
97. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell. Dev. Bi. 1996, 12:697-715.
98. Andersson M., Fromell K., Gullberg E., Artursson P., Caldwell K.D. Characterization of surface-modified nanoparticles for in vivo biointeraction. A sedimentation field flow fractionation study. Anal. Chem. 2005, 77:5488-5493.
99. Hersel U., Dahmen C., Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24:4385-4415.
100. Bellis S.L. Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials 2011, 32:4205-4210.
101. Montet X., Funovics M., Montet-Abou K., Weissleder R., Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 2006, 49:6087-6093.
102. Gref R., Couvreur P., Barratt G., Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 2003, 24:4529-4537.
103. Weissenböck A., Wirth M., Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J. Control. Release 2004, 99:383-392.
104. Mo Y., Lim L.-Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J. Control. Release 2005, 108:244-262.
105. Mo Y., Lim L.Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J. Control. Release 2005, 107:30-42.
106. Gao X., Wang T., Wu B., Chen J., Chen J., Yue Y., Dai N., Chen H., Jiang X. Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. BBBC 2008, 377:35-40.
107. Jeong Y.I., Seo S.J., Park I.K., Lee H.C., Kang I.C., Akaike T., Cho C.S. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl l-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm. 2005, 296:151-161.
108. Yin Y., Chen D., Qiao M., Wei X., Hu H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control. Release 2007, 123:27-38.
109. Marasco D., Perretta G., Sabatella M., Ruvo M. Past and future perspectives of synthetic peptide libraries. Curr. Protein Pept. Sci. 2008, 9:447-467.
110. Smith G.P., Petrenko V.A. Phage display. Chem. Rev. 1997, 97:391-410.
111. Koivunen E., Arap W., Rajotte D., Lahdenranta J., Pasqualini R. Identification of receptor ligands with phage display peptide libraries. J. Nucl. Med. 1999, 40:883-888.
112. Yoo M.-K., Kang S.-K., Choi J.-H., Park I.-K., Na H.-S., Lee H.-C., Kim E.-B., Lee N.-K., Nah J.-W., Choi Y.-J., Cho C.-S. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010, 31:7738-7747.
113. Fievez V., Plapied L., Plaideau C., Legendre D., des Rieux A., Pourcelle V., Freichels H., Jerome C., Marchand J., Preat V., Schneider Y.J. In vitro identification of targeting ligands of human M cells by phage display. Int. J. Pharm. 2010, 394:35-42.
114. Koivunen E., Wang B., Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 1995, 13:265-270.
115. Pasqualini R., Koivunen E., Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 1997, 15:542-546.
116. McGuire M.J., Samli K.N., Johnston S.A., Brown K.C. In vitro Selection of a Peptide with High Selectivity for Cardiomyocytes in vivo. J. Mol. Biol. 2004, 342:171-182.
117. Doorbar J., Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J. Mol. Biol. 1994, 244:361-369.
118. Oyama T., Rombel I.T., Samli K.N., Zhou X., Brown K.C. Isolation of multiple cell-binding ligands from different phage displayed-peptide libraries. Biosens. Bioelectron. 2006, 21:1867-1875.
119. Done D., Ashish G., Efrosini K. PR_b-targeted PEGylated liposomes for prostate cancer therapy. Langmuir 2008, 24:13518-13524.
120. Veronika M., Jessica M.R., Laurel T.B., Lotta B., Emilia P., Alain D., Lina E.F., Sebastian L., Diana M.T., Mika L., Cecilia S. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. 2011, 19:1538-1546.
121. Samli K.N., McGuire M.J., Newgard C.B., Johnston S.A., Brown K.C. Peptide-mediated targeting of the islets of Langerhans. Diabetes 2005, 54:2013-2108.
122. Goldstein I.J., Hughes R.C., Monsigny M., Osawa T., Sharon N. What should be called a lectin?. Nature 1980, 285:66.
123. Irache J.M., Durrer C., Duchene D., Ponchel G. Preparation and characterization of lectin-latex conjugates for specific bioadhesion. Biomaterials 1994, 15:899-904.
124. Irache J.M., Durrer C., Duchene D., Ponchel G. Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Pharm. Res. 1996, 13:1716-1719.
125. Lehr C.M., Bouwstra J.A., Kok W., Noach A.B., de Boer A.G., Junginger H.E. Bioadhesion by means of specific binding of tomato lectin. Pharm. Res. 1992, 9:547-553.
126. Russell-Jones G.J., Veitch H., Arthur L. Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int. J. Pharm. 1999, 190:165-174.
127. Zhang N., Ping Q., Huang G., Xu W., Cheng Y., Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 2006, 327:153-159.
128. Liu J., Gong T., Wang C., Zhong Z., Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int. J. Pharm. 2007, 340:153-162.
129. Leonardo M., Elena M.V.A., Carlo S., Daniela A. Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjug. Chem. 2011, 22:664-672.
130. Fievez V., Plapied L., des Rieux A., Pourcelle V., Freichels H., Wascotte V., Vanderhaeghen M.-L., JerÔme C., Vanderplasschen A., Marchand-Brynaert J., Schneider Y.-J., Préat V. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur. J. Pharm. Biopharm. 2009, 73:16-24.
131. Kim W.J., Yockman J.W., Lee M., Jeong J.H., Kim Y.H., Kim S.W. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J. Control. Release 2005, 106:224-234.
132. Gullberg E. Particle Transcytosis Across the Human Intestinal Epithelium: Model Development and Target Identification for Improved Drug Delivery 2005, Acta Universitatis Upsaliensis.
133. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
134. Neff J.A., Caldwell K.D., Tresco P.A. A novel method for surface modification to promote cell attachment to hydrophobic substrates. J. Biomed. Mater. Res. 1998, 40:511-519.